Introduction
Chronic pulmonary inflammation, triggered by an imbalance in the production of pro-and anti-inflammatory mediators, leads to significant tissue destruction and affects lung function in a large number of diseases including acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF) and cystic fibrosis (CF).
nuclear transfection significantly. We determined the effect of cytoplasmic NFB decoys on bleomycin-induced inflammation. We transfected mice with 'naked' decoy and scrambled ODN (500 g) 1 h before intratracheal administration of bleomycin. We measured IL6 secretion in BALF and lung homogenates and total and differential cell counts in BALF 5 days after bleomycin administration. We did not detect a difference between NFB decoy and scrambled ODN-treated animals in any of the parameters tested. We suggest that access of ODN to the nucleus of airway epithelial cells is a key problem, limiting the efficacy of such decoy strategies, as well as attempts at gene repair.
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The release of pro-inflammatory mediators plays a central role in bleomycin-induced lung inflammation. 5, 6 Expression of many pro-inflammatory mediators, including cytokines such as tumour necrosis factor alpha (TNF-␣) and interleukin , as well as cell adhesion molecules, is regulated by the transcription factor nuclear factor kappa B (NFB). 7 NFB is a member of the Rel protein family. The most common form responsible for proinflammatory action is a heterodimer consisting of a p50 and a p65 subunit. NFB is expressed in most cell types, but is retained in the cytoplasm by a family of specific inhibitors (inhibitor kappa B, IB). Following exposure to an inflammatory stimulus, the inhibitor is phosphorylated and dissociates from the NFB heterodimer. This exposes the previously masked nuclear localisation signal and enables the transcription factor to rapidly enter the nucleus, where it binds to NFB consensus binding sites in the promoter region of many pro-inflammatory genes. 7 A crucial role for NFB in bleomycin-induced lung inflammation has previously been documented. 8 NFB activation is likely to occur through reactive oxygen species, which are generated after bleomycin administration. 9 Potent anti-inflammatory agents, such as steroids and interleukin 10 (IL10) have been shown to work at least in part through inhibition of NFB. [10] [11] [12] To date steroids and non-steroidal anti-inflammatory drugs have been of limited value in ARDS, IPF and CF, and new treatment options need to be explored. NFB decoy oligonucleotides, which resemble consensus binding sites for NFB, and therefore inactivate the transcription factor have been used successfully in several inflammatory disease animal models. [13] [14] [15] We have previously demonstrated that NFB decoy oligonucleotides (ODN) reduced basal and LPS-stimulated IL-8 secretion in a CF airway epithelial cell line, 16 but their effect in models of pulmonary inflammation in vivo has not yet been investigated. We have, therefore, assessed the effect of NFB decoy ODN administration during the acute phase of bleomycininduced pulmonary inflammation in C57Bl/6 mice in vivo.
Results

Biodistribution of NFB decoys in the lung after topical administration
We compared the biodistribution of lipid-complexed or 'naked' NFB decoy ODN (80 g) after pulmonary transfection. The overall distribution in the airways and alveolar region was similar (Figure 1a -d) and transfection efficiency in the conducting airways was 66% ± 4.6 and 66% ± 6.7 after lipid-complexed and 'naked' ODN transfection, respectively (six images/mouse, n = 3 in each group) (Figure 2 ). However, the vast majority of the signal was located in the cytoplasm of airway and alveolar epithelial cells. In contrast to lipid-complexed ODN, the administered concentration of 'naked' ODN can readily be increased. We, therefore, administered 500 g per animal to determine if the transfection of nuclei in the lung increased. Although 97.9% ± 0.6 and 76.0% ± 4.3 of alveolar and airway epithelial cells were respectively transfected (six images/mouse, n = 3 in each group), decoy deposition in the nuclei was only 0.5% ± 0.2 and 0.6% ± 0.3 of alveolar and airway cells, respectively ( Figures 3 and 4) . Five days after administration NFB decoy ODN were still detectable in the cytoplasm, but not in the nuclei of alveolar and airway epithelial cells (Figure 4c, d) .
The effect of NFB decoy administration in the bleomycin mouse model It is unclear, whether NFB decoy ODN have to enter the nucleus to prevent the transcription factor from reaching the consensus binding sites in the promoter of inflammatory genes, or if binding of the decoy ODN to NFB could occur in the cytoplasm. Here, we determined the effect of cytoplamic NFB decoy ODN deposition on bleomycininduced inflammation. The animals were transfected with 'naked' ODN (500 g/animal), because the mortality of bleomycin-treated animals increased markedly in groups that also received liposome/DNA complexes 1 h before bleomycin (bleomycin plus liposome/DNA complexes: 88% dead, bleomycin only: 10% dead). In addition, as noted above, the use of 'naked' ODNs allowed us to administer a higher dose per animal.
Acute inflammation was assessed by IL-6 levels in lung homogenate and broncho-alveolar lavage fluid (BALF) and total and differential cell counts in BALF. We first determined IL-6 levels 1, 3 and 5 days after bleomycin or saline administration. Increased IL-6 production was detected in BALF and lung homogenates at all timepoints ( Figure 5a , b), but the difference between saline and bleomycin-treated animals was highest 5 days after administration (day 5: BALF and lung homogenate, P Ͻ 0.001 compared with day 5 saline and untreated animals, n = 13-16 for each group). This time-point was therefore chosen to determine the effect of NFB decoy ODN. Interestingly, saline lead to a transient increase in IL-6 in lung homogenate 1 day after administration, which returned to baseline values 3 days after administration (P Ͻ 0.05 compared with untreated animals, n = 7-13 each group). However, a saline-mediated increase in IL-6 was not detectable in BALF. Administration of NFB decoy ODN did not alter IL-6 levels in lung homogenate or BALF (Figure 6a, b) , when compared with scrambled
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Figure 5 IL-6 in lung homogenate and broncho-alveolar lavage fluid after bleomycin administration. IL-6 was measured 1, 3 and 5 days after bleomycin administration. (a) IL-6 levels in broncho-alveolar lavage (BALF), (b) IL-6 levels in lung homogenate ( * * * P Ͻ 0.001 when compared when untreated or day 5 saline-treated animals, n = 5-16 animals per group).
Figure 6 Effect of NFB decoy ODN on IL-6 levels in bleomycin-treated mice. IL-6 was measured 5 days after decoy ODN and bleomycin administration. (a) IL-6 levels in broncho-alveolar lavage (BALF); (b) IL-6 levels in lung homogenate ( * * * P Ͻ 0.001, when compared with saline-treated animals, n = 7-16 animals per group).
oligos or bleomycin-only treated animals. Serum IL-6 in all groups was below the detection limit of the assay (data not shown). BALF total and differential cell counts were also assessed 5 days after decoy and bleomycin administration (Table 1) . There was no difference between untreated and saline-treated animals, but as expected bleomycin-treated animals showed a 3.5-fold increase in total cell number ( * * * P Ͻ 0.001 compared with untreated or saline-treated animals, n = 10-15 per group). Further, differential cell counts showed a significant increase in the proportion of neutrophils and lymphocytes, after bleomycin ( * * P Ͻ 0.01 for both cell types when compared with saline-treated animals n = 10-15 for each group). However, NFB decoys produced no significant change in either total or differential cell counts compared with scrambled ODNs. Administration of 'naked' ODNs to the lung did not increase IL-6 or inflammatory cells over bleomycin-induced levels.
Discussion
We have determined the biodistribution of topically administered lipid-complexed or 'naked' NFB decoy ODN in the murine lung and have assessed the effect of NFB decoy ODN on acute inflammation in a murine bleomycin model. Intratracheal administration of lipidcomplexed or 'naked' ODN resulted in efficient cytoplasmic, but not nuclear transfection of airway epithelial cells and alveolar cells in vivo. Cytoplasmic deposition of NFB decoys did not reduce bleomycin-induced lung inflammation.
Although small DNA fragments (Ͻ50 bp) have been widely used as decoy and antisense molecules in vivo, [13] [14] [15] 17, 18 their biodistribution after topical administration to the lung has not yet been studied. We have shown that both 'naked' and lipid-complexed decoy ODN have similar biodistribution and subcellular localisation in the lung. Although the vast majority of alveolar and airway epithelial cells showed cytoplasmic transfection, nuclear transfection was very inefficient. At the highest dose only approximately 1:200 of alveolar or airway nuclei contained fluorescently labelled ODN. Further, this number is likely to be an overestimation, because our confocal microscopy cannot discriminate fluorescent signal at the inner edge of the nucleus, from signal that appears nuclear, but is in reality sitting in a cytoplasmic invagination. We analysed six images from each animal and counted between 800 and 2500 cells for each animal. In these cells nuclei will be randomly cut at different positions. Although we cannot exclude that more careful analysis of individual nuclei in different planes would reveal more signal in some cells, it is unlikely that this would alter the calculated transfection efficiency greatly. We are not able to assess, how many FITC-labelled decoys will be required to see a fluorescent signal. However, in our view it is likely to be more than one molecule. We considered converting the fluorescent signal into a rough calculation of decoy amount by using a standard curve. However the intensity of the fluorescent signal is not only determined by the amount of decoy present, but also by the tissue processing and the cell environment. It is therefore not possible to extrapolate from a standard curve. The fluorescent signal of lipidcomplexed and 'naked' decoy ODNs were very similar, with a punctuate pattern. The nuclear pore complex (NPC) generally allows molecules with a molecular weight below 40-60 kDa to enter through passive diffusion. 19 The NFB decoy ODN used in the study, which has a molecular weight of 13.2 kDa, should be small enough to enter the nucleus easily. We propose that the decoy ODN may be either restrained in vesicles, and therefore not have access to the NPC, or that transport of DNA through the NPC does not follow the same size restrictions as proteins. Interestingly, we and others have demonstrated that nuclei of hepatocytes can be transfected very efficiently with decoy ODN. 20, 21 The distribution in hepatocytes is different, with a markedly more diffuse pattern (E Fox, personal communication), which may reflect a difference in subcellular localisation, favourable for nuclear uptake. Thus uptake of decoy ODN appears to be cell type-specific. It will be interesting to assess whether addition of nuclear localisation signals (NLS) to decoy ODN or plasmid DNA, shown to be promising in Zebrafish embryos and HeLa cells, [22] [23] [24] will be effective in airway epithelial cells in vivo.
The decoy ODNs used in this study were phosphorothioated and therefore resistant to degradation. Geary et al 25 have shown that 24 h after i.v. injection at least 50% of phosphoratioated ODN in the lung are intact. However, we cannot exclude that the decoy ODNs were damaged through the bleomycin, which is known to intercalate between DNA base pairs and to generate free radicals that further damage the DNA. 26 Following bleomycin administration, a complex spatial and temporal network of inflammatory mediators is upregulated. 3, 6, 27, 28 We chose to measure the effect of NFB decoy ODN on IL-6 production. IL-6 has been shown to be involved in bleomycin-induced inflammation 28, 29 and is produced by a variety of cell types, including epithelial cells and macrophages. 30, 31 There is also good evidence that secretion of IL-6 is regulated through NFB 32 and NFB consensus binding sites have been identified in the promoter of the IL6 gene. 33, 34 We also measured the effect of NFB decoy ODN on total and differential cell counts, as it is well documented that inflammatory cell chemokines, such as macrophage inflammatory protein-1␣ and macrophage inflammatory protein-2, which are involved in the generation of bleomycin-induced lung damage, 28, 35 are regulated through NFB. 36 Topical administration of NFB decoy ODN did not attenuate IL-6 or total and differential cell counts in the bleomycin model. This is in contrast to previous reports, which demonstrated that strategies aimed at decreasing NFB through anti-oxidant therapy 8 or p65 antisense ODN therapy 18 attenuated bleomycin-induced lung inflammation. Several explanations may account for these differences. Firstly, although almost every lung cell and inflammatory cell has been implicated in the pathogenesis of bleomycin-induced pulmonary fibrosis, the relative importance of individual cell types in this process has not been established yet. For example, the proinflammatory cytokine IL-6 can be produced by alveolar and bronchial epithelial cells, 37, 38 as well as alveolar macrophages. 39 Smith et al 28 have proposed a cytokine network where initially TNF-␣ and IL-6 are secreted from airway epithelial cells and resident alveolar macrophages, leading to recruitment and stimulation of additional inflammatory cells into the lesion area. These inflammatory cells are mainly responsible for the inflammation and fibrotic lesions in the bleomycin treated lung. It is unlikely that our treatment protocol allowed efficient transfection of alveolar macrophages, because the NFB decoy ODN was administered only once, 30 min before bleomycin challenge. We may, therefore, have not targeted the appropriate cell type (macrophages, inflammatory cells) to achieve a long-term (day 5) reduction in inflammation. We have mentioned earlier cell and tissue type specific differences in ODN uptake. NFB decoy ODN should theoretically be able to bind and therefore inactivate NFB in both the cytoplasm and nucleus. Our study suggests that either nuclear deposition of NFB decoys is crucial or the decoys are deposited into cytoplasmic compartments not amenable to NFB. Thus, as for plasmid-mediated gene transfer, the lung appears to be a well-defended site for oligonucleotide-based therapies. This is also of considerable relevance to attempts at pulmonary gene repair for diseases such as CF, where nuclear deposition of oligonucleotides is mandatory.
In summary, we show that oligonucleotides administered topically to the airways can reach a cytoplasmic, but not a nuclear compartment. The lack of effect of NFB decoys on the bleomycin model of lung inflammation is a likely consequence of this. Efforts need to be directed at increasing the nuclear localisation of lungdirected oligonucleotide therapies.
Materials and methods
NFB decoy oligonucleotides
Phosphorothioated and HPLC-purified NFB decoy and scrambled ODN were purchased from Hybaid Interactiva (Ashford, UK). For the biodistribution studies 5' fluorescein (FITC) labelled ODN were used. The ODN were resuspended in sterile water to a concentration of 1.6 mg/ml and the forward and reverse ODN were annealed over 2 h using a temperature gradient ranging from 80°C to 25°C as previously published. 40 Gene Therapy Murine bleomycin model and NFB decoy transfection C57Bl/6 mice (female, 16-20 g), which are sensitive to bleomycin-induced lung inflammation 41 were used. Mice were anaesthetised (Avertin 42 ) and a tracheotomy was performed. Bleomycin-sulphate (0.075 units in 0.9% saline, Sigma-Aldrich, Poole, UK) in a total volume of 100 l, or saline only, was injected directly into the trachea using an insulin syringe. The skin incision was closed with two sutures. For the decoy or scrambled ODN transfection, which was carried out 30 min before bleomycin administration, mice were anaesthetised with metofane (Medical Developments, Springvale, Australia). The DNA solution (80 or 500 g/mouse) was placed as a single 100 l bolus into the nasal cavity and the solution sniffed into the lungs. Biodistribution studies were carried out in the absence of bleomycin and for some animals the decoy ODN was complexed to the cationic lipid GL67 (Genzyme, Framingham, USA) as previously described. 43 Eighty g of lipid-complexed ODN in 100 l total volume was the highest dose that could be safely delivered per mouse, because DNA and lipid concentrations and molar ratios are important for correct liposome formation.
Biodistribution of fluorescein-labelled NFB decoy ODN in the lung
Twenty-four hours after decoy ODN administration, the animals were culled, the trachea exposed and the lungs inflated with 4% paraformaldehyde (pH 7.3) using a catheter (20 gauge, Ohmeda, Sweden) inserted into the trachea. The lungs were than removed en bloc and placed into 4% paraformaldehyde for a further 12-18 h. The tissues were processed and paraffin-embedded using standard procedures and 5 m sections cut. Sections were counterstained with DAPI and mounted with DPX (VWR-International, Poole, UK). Decoy ODN distribution and transfection efficiency were determined using confocal microscopy with an optical thickness of 1 m (60× objective). A total of six individual images from different regions of the lung per animal were analysed. The total cell number analysed varied for each group, and is stated in the Figure legends.
Broncho-alveolar lavage and tissue processing
At the indicated time-points after decoy and bleomycin administration, mice were culled. For the bronchoalveolar lavage (BAL) a catheter (20 gauge, Ohmeda) was placed into the trachea and the lungs washed with 3 × 0.5 ml of PBS. On average 80% of BAL fluid (BALF) was retrieved, spun for 5 min at 3000 r.p.m. to remove cellular components and then frozen at -80°C. Lung tissue was snap frozen in liquid nitrogen after harvesting and homogenized in 600 l 0.25 M Tris-HCl, pH 8.0. Following three freeze/thaw cycles the tissue lysates were spun for 10 min at 13 000 r.p.m. and the supernatant frozen at -80°C. The protein concentration in the lung homogenates was determined using a modified Folin-Lowry assay. 44 
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Total and differential cell counts Following centrifugation of the BALF, the cell pellet was resuspended in 100 l PBS. Twenty l of this were stained with the nuclear stain crystal violet 1:1 diluted with water (VWR-International) and total cells (excluding erythrocytes) were counted in a hematocytometer. For the differential cell counts 10 6 cells in 100 l were cytospun (Shandon Cytospin3) for 4 min at 500 r.p.m. using pre-wetted (400 l PBS) cytofunnels. The slides were airdried (5 min), fixed in methanol (5 min) and stained with Grunwald (VWR-International) and Giemsa stains (VWR-International) for 5 min each. After air-drying the slides were mounted with DPX mounting medium (VWR-International) and the proportion of macrophages, neutrophils and lymphocytes was determined in 200 cells per sample.
ELISA assays IL-6 levels were measured in lung homogenate and BALF using a murine IL-6 ELISA (R&D, Oxford, UK) according to the manufacturer's recommendations.
Statistical analysis
All values are expressed as the mean ± s.e.m. for convenience and n refers to the number of animals used. The data were analysed by the Mann-Whitney U test, and the null hypothesis rejected at P Ͻ 0.05.
